In our study we also conducted correlative analysis between the magnitude of response to ICB (magnitude of response characterised by alteration in PBMC secretion of IFN-γ in PBMC culture following 5 days of T cell activation) in expanded PBMCs with circulating serum proteins in cancer patients on POD 0, 1 and 7 to determine if there was a circulating factor that might indicate if the use of ICB could enhance Th1 immune responses in a patients PBMCs. This evidence concerns the gene IFNG and cancer.